Moving forward, one could envision using a BCAT1 inhibitor to “soften up” a tumor before hitting it with chemotherapy or a targeted agent—the metabolic stress might make cancer cells less able to cope with the subsequent assault. Here, BCAT1 is linked to neoplasm.